Product Description
ALETA-001 reactivates the CD19 CAR-T cells by effectively 'recoating' the cancer cell with the target CD19 proteins and restoring the CAR-T cells ability to recognize and engage the cancer cell. (Sourced from: http://www.aletabio.com/science/)
Mechanisms of Action: CD19 Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aleta BioTherapeutics
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: Cancer Research UK
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphoma, Non-Hodgkin|Mantle-Cell Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06045910 |
CRUKD/23/001 | P2 |
Recruiting |
Lymphoma, Non-Hodgkin|Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma|Follicular Lymphoma |
2028-02-01 |
2025-06-03 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |